Abstract:Background Activation of anticancer T cell immunity by checkpoint inhibition has become a key tool in the clinical management of cancer, but efficacy is limited in part by the suppressive activity of myeloid cells. Reprogramming myeloid cells from a suppressive into an immune-enhancing state is a goal of significant translational interest. Using preclinical and clinical studies, we investigated the potential of JAK inhibitors to enhance the efficacy of checkpoint inhibitors in a myeloid-dependent manner. Methods The combination therapy of systemic treatment with the JAK inhibitor ruxolitinib with anti-PD1 + anti-CTLA4 was evaluated for efficacy and biomarkers compared to checkpoint inhibitors (ICI) alone in four murine immunocompetent models of cancer. Tumor-infiltrating, blood and lymphoid organ immune cells were phenotyped using single-cell transcriptomics, functional assays and flow cytometry. The combination therapy was clinically tested in an investigator-initiated Phase I/II clinical trial of ruxolitinib with nivolumab in relapsed or refractory Hodgkin lymphoma (NCT03681561). Patients who previously failed to respond to ICI received ruxolitinib for 1 week then nivolumab every 4 weeks concurrent with ruxolitinib. Hematologic, transcriptomic and flow cytometric analyses were performed on peripheral blood collected at baseline and after ruxolitinib treatment. Results The ruxolitinib + ICI combination was superior to ICI in 3/4 of the tumor models examined in controlling tumor growth. Compared to ICI alone, tumor sizes were reduced by >50% in the MC38 (mean volume 123.1 vs 283.2 mm3, n=9 per group, p=0.0094), LLC1 and A20 models (survival hazard ratio 0.47, n=30 per group, p=0.025). Remarkably, we observed a broad shift of tumor monocytes and granulocytes from a suppressive into an immunostimulatory state characterized by the expression of MHC-II and the ability to stimulate T cell proliferation. Depleting monocytic or granulocytic cells abrogated the beneficial effect of ruxolitinib. Hodgkin lymphoma patients in the ruxolitinib with nivolumab trial exhibited a disease control rate of 63% (12/19) including 5 complete responses. Ruxolitinib treatment in these patients did not impair T cell numbers or cytokine production but significantly reduced the neutrophil-to-lymphocyte ratio (NLR, mean difference -0.82, n=14, p=0.0023) and the percentage of LOX1+ granulocytic suppressor cells in peripheral blood (mean 0.27 of baseline, p=0.0009). The reduction in NLR was significantly greater in complete responders than in progressive disease patients (mean -2.6 vs -0.58, respectively, p=0.023). Conclusions The combination of ruxolitinib with ICI was effective in preclinical models and in a Phase I/II Hodgkin lymphoma clinical trial, identifying JAK inhibition with ICI as a promising myeloid-modulating immunotherapy. Trial Registration The clinical trial identifier number is NCT03681561. Ethics Approval This work was approved by the Institutional Review Boards of the University of Minnesota (STUDY00001341) and The Scripps Research Institute (IRB-19–7408, IRB-21–7803).

Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients

The Progress of PD-1 Inhibitors in Small-Cell Lung Cancer

JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma

847 Optimal Dose Selection of ADG126 (a Masked Anti-Ctla-4 SAFEbody®) with Significantly Widened Therapeutic Index Compared to Ipilimumab in Combination with Anti-Pd-1 Antibodies Informed by QSP Modeling

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity Via Immunogenic Cell Death and Macrophage Reprogramming

Combined Inhibition Of Tgf- Signaling And The Pd-L1 Immune Checkpoint Is Differentially Effective In Tumor Models

The combination of a PTP1B inhibitor, TNFR2 blocker, and PD‐1 antibody suppresses the progression of non‐small cell lung cancer tumors by enhancing immunocompetence

Anlotinib enhanced CD8 + T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer

Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model

A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer

CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

A phase Ib study evaluating the safety and efficacy of IBI310 plus sintilimab in patients with advanced non‐small‐cell lung cancer who have progressed after anti‐PD‐1/L1 therapy

Targeting TNFR2 to overcome acquired adaptive resistance to immune checkpoint blockade

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors

TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma

Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases

Suppression of Type I Ifn Signaling in Tumors Mediates Resistance to Anti-Pd-1 Treatment That Can Be Overcome by Radiotherapy

Functional and molecular characterization of PD1+ tumor-infiltrating lymphocytes from lung cancer patients

Addition of anti-TIM3 or anti-TIGIT Antibodies to anti-PD1 Blockade Augments Human T cell Adoptive Cell Transfer